The government on Wednesday announced that all seven manufacturers of Remdesivir in the country have been asked to ramp up production to full capacity by next week. This announcement came after the direction against reports of shortages of critical drug.
Remdesivir is considered a key antiviral drug in the fight against Coronavirus, especially in adult patients with severe complications and co-morbidities.
Mansukh Mandaviya, Minister of State for Chemical and Fertilizers said, “There are seven players who produce Remdesivir. I have asked all players to ramp up production to full capacity by next week. The drug’s API is manufactured in India so there won’t be a problem.”
Mandaviya said these seven manufacturers – Mylan, Hetero, Jubiliant Life Sciences, Cipla, Dr. Reddy’s, Zydus Cadila, and Sun Pharma – have a monthly production capacity of 31.60 lakh vials.
He added letters have been dispatched to all these drug makers to ramp up production.
Mandaviya said, of the 31.60 lakh vials, Hetero produces 10.50 lakh vials a month, Cipla makes 6.20 lakh vials, 5 lakh vials are produced by Zydus Cadila and 4 lakh vials are produced by Mylan.
The remaining drugmakers produce vials in the range of 1 lakh and 2.5 lakh a month, he added.
The Madhya Pradesh government has decided to obtain Remdesivir injections so that they could be provided free of cost for the treatment of critical Covid-19 patients from the economically weaker sections.